research BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
JAK inhibitors help regrow hair in alopecia areata, but their long-term safety is still unclear.
Search
for
Sort by
Research
150-180 / 1000+ resultsresearch Review of the Literature: Topical JAK Inhibitors Showing Promise for Hair Loss!
Topical JAK inhibitors may help treat hair loss.
research JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
research Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
Tofacitinib may be safe and effective for treating certain skin conditions in children.
research 44182 Treatment with Oral Janus Kinase Inhibitors in Adults Patients with Alopecia Areata: A Systematic Review and Meta-Analysis
Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
research Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
research Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
research Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
Blocking Janus kinase 1 helps stop inflammation and regrow hair, making it a good treatment for hair loss from alopecia areata.
research Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
research 705 Particulate matter induces inflammatory response in human outer root sheath cells via oxidative stress-dependent MAPK and JAK-STAT signaling pathways
Particulate matter causes inflammation in hair cells, potentially harming hair growth.
research Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with Janus Kinase Inhibitors
Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.
research Drug Armamentarium for alopecia areata
No cure exists for alopecia areata, and treatments are personalized.
research Safety and efficacy of tofacitinib in 97 alopecia areata patients
Tofacitinib is an effective and safe treatment for alopecia areata.
research Shared Decision-Making, Therapeutic Choice, and Decisional Regret in Patients With Alopecia Areata
Patients with alopecia areata feel less regret about treatment decisions when they are involved in the decision-making process.
research Effectiveness and safety of oral Janus kinase inhibitors in patients aged ≤12 with alopecia areata: a systematic review and meta-analysis
Janus kinase inhibitors can help children with alopecia areata regrow hair but may have some risks.
research Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
research Alopecia Areata: A Complex Cytokine Driven Disease
Alopecia areata is a hair loss disease caused by complex immune reactions, and new targeted treatments show promise.
research APECED: JAK Inhibition in an Adult Case with Long-Term Follow-up
JAK inhibitors may help improve symptoms in adults with APECED.
research Alopecia areata: a review of diagnosis, pathogenesis and the therapeutic landscape
New treatments for alopecia areata show promise, but standardized guidelines are needed.
research Janus Kinase inhibitors in dermatology: a review
JAK inhibitors effectively treat skin conditions and topical forms are safer.
research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
Tofacitinib may help treat severe hair loss, but more research is needed.
research The JAK/STAT signaling pathway: from bench to clinic
The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
research Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
Blocking JAK-STAT signaling can lead to hair growth.
research MODERN BIOLOGICAL TREATMENT METHODS FOR ALOPECIA AREATA: A COMPREHENSIVE REVIEW
JAK inhibitors show promise for treating alopecia areata, but more research is needed.
research Alopecia areata
Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
research Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata
Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
research A new era for alopecia areata: New treatments and improved knowledge of the condition
Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
research POS0080 TOFACITINIB TREATMENT IN CHILDREN WITH RHEUMATIC DISEASES: SINGLE-CENTER EXPERIENCE
Tofacitinib is a promising treatment for children with rheumatic diseases.
research BH14 Irish dermatologists’ experience with Janus kinase inhibitors in alopecia areata
Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.